Shenzhen - Delayed Quote • CNY
Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)
At close: 3:04 PM GMT+8
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Wang Chao | General Manager | -- | -- | 1982 |
| Mr. Shicheng Li | Financial Director | -- | -- | 1982 |
| Mr. Jiguang Zhao | Deputy General Manager | -- | -- | 1975 |
| Mr. Maorong Yu | Secretary of the Board & Deputy GM | -- | -- | 1981 |
Staidson (Beijing) BioPharmaceuticals Co., Ltd.
No. 36, Jingha 2nd Road
Beijing Economic and Technological Development Zone
Beijing, 100176
China
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 555
Description
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.
Corporate Governance
Staidson (Beijing) BioPharmaceuticals Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- May 17, 2019Ex-Dividend Date
Upcoming Events
Upcoming Events Information Not Available